Morgan Fox: The Symbolism and Reality of Federal Cannabis Rescheduling
Tue / Oct 8th PODCAST
The DEA’s public hearing regarding changing the classification for cannabis is scheduled for December 2nd, but what would Schedule III… Read More
The Drug Enforcement Agency (DEA) is a federal law enforcement agency whose main job is to halt drug trafficking and distribution. Their focus on cannabis has become increasingly questionable as legal recreational use takes the world by storm. Articles including the DEA can be found here:
Tue / Oct 8th PODCAST
The DEA’s public hearing regarding changing the classification for cannabis is scheduled for December 2nd, but what would Schedule III… Read More
Mon / Sep 30th
The DEA is proposing revised 2024 and new 2025 production quotas for research-grade psychedelics including psilocybin, psilocin, and ibogaine. The agency says the new production rates are needed to drive new research.
Tue / Aug 27th
The DEA has scheduled a December 2 hearing to review expert opinions on the proposed rescheduling of cannabis to a Schedule III drug, adding a procedural step that could delay the process until after the November election.
Mon / Jul 29th
About nine out of every ten comments submitted to the DEA on the proposal to federally reschedule cannabis either favored the reforms or called on the government to go further and remove cannabis entirely from the federal drug schedule.
Wed / May 29th
While federal lawmakers consider banning most hemp-derived cannabinoid products, the hemp industry is facing another potential threat after a DEA official said the federal 0.3% delta-9 THC cap also applies to delta-9 THCA, which is a similar compound.
Wed / May 22nd
The Drug Enforcement Administration and Department of Justice on Tuesday published the rule proposal for moving cannabis to Schedule III under the Controlled Substances Act (CSA). The publication kicks off a 61-day public comment period, a CSA requirement.
Thu / May 16th
Joe Biden has announced that the US Justice Department is moving cannabis from Schedule I to Schedule III. In his announcement, he stated that he is committed to “righting the wrongs” of prohibition, though Schedule III status doesn’t do anything specific to help those currently incarcerated.
Tue / Apr 30th
The DEA has reportedly agreed to reschedule cannabis under Schedule III of the Controlled Substances Act, in accordance with the FDA’s recent recommendation. While this development could loosen financial restrictions for brands operating in state markets, advocates have pointed out that it does not resolve the ongoing social injustices surrounding cannabis criminalization, and that it could benefit larger corporate entities that are angling to dominate the market.
Thu / Apr 25th
Eight months after the federal Department of Health and Human Services recommended moving cannabis from Schedule I to Schedule III, a coalition of Congressional lawmakers this week urged the DEA to make its decision as quickly as possible.
Fri / Apr 12th
FDA Commissioner Robert Califf said during testimony before a House committee this week that there’s “no reason” for the DEA to “delay” its cannabis rescheduling decision.
Tue / Mar 12th
Wed / Jan 31st
Twelve Senate Democrats have urged the Biden Administration to remove cannabis from the Controlled Substances Act, countering a recent HHS recommendation for Schedule III that is currently being reviewed by the DEA.
Thu / Jan 4th
Is the DEA planning to change the scheduling status of cannabis under the Controlled Substances Act? In a leaked letter to Congress, the agency has asserted their control over any decision about rescheduling or descheduling the plant.
Mon / Dec 11th
After Georgia made it legal for pharmacies to dispense low-THC cannabis oils in October, the Drug Enforcement Administration has apparently sent warning letters to several pharmacies in the state.
Fri / Sep 22nd
Fourteen Republican lawmakers have sent a letter to DEA Administrator Anne Milgram, urging the agency to reject the recent Department of Health and Human Services recommendation to reclassify cannabis from Schedule I to Schedule III under federal law.
Thu / Aug 31st
In a letter to DEA Administrator Anne Milgram, U.S. Rep. Matt Gaetz (R-FL) asked why the agency has not taken steps to reconsider cannabis’ status as a Schedule I substance.
Wed / Aug 16th
A recently revealed letter confirms that the U.S. Drug Enforcement Administration considers delta-8 THC that has been synthesized from hemp-derived CBD — so, the vast majority of consumer delta-8 products — to be federally illegal.
Wed / Aug 2nd
Cannabis research company MMJ International Holdings is preparing a lawsuit against the Drug Enforcement Administration (DEA) for allegedly failing to follow federal law as it concerns the cultivation of pharmaceutical cannabis.
Tue / May 23rd
The Drug Enforcement Administration (DEA) appears to support considering synthetic cannabinoids that contain THC — including hemp-derived delta-8 THC — as controlled substances under federal law, according to a recent agency conference presentation.
Tue / Feb 14th
The DEA declared this week that novel cannabinoids including delta-9 and -8 THCO are illegal, even when sourced from federally legal hemp crops.
Fri / Oct 7th
DEA Museum historian Kasey Sease, Ph.D. admitted that the reasons for criminalizing drug use were based on racial, ethnic, and class prejudice.
Wed / Oct 5th
DEA pharmaceutical cannabis license-holder Biopharmaceutical Research Company has raised $20 million in its Series A funding round.
Thu / Sep 15th PODCAST
Shane Pennington is the New York-based counsel for Vicente Sederberg LLP, a national cannabis law firm that represents cannabis industry clients and works on state and local cannabis policy reform.
Tue / Jun 21st
The DEA reported an uptick in cannabis arrests and seizures for last year, marking the highest federal enforcement figures since 2011.
Website & branding by the Ganjapreneur in-house agency:
Uplifted cannabis industry branding & marketing.